Radiolabeled 68Ga-PSMA-11 and 18F-DCFPyL were approved by the FDA in 2020 and 2021 for PC patients at high risk for pelvic nodal metastases and biochemical recurrent prostate cancer (Eder et al., 2012). The gene discussed is FOLH1; the disease is prostate carcinoma.